Type 2 Diabetes

The indication makes insulin icodec the first new class of basal insulin to reach US patients in more than 2 decades.

This episode features discussion around 3 recent announcements from Novo Nordisk, Eli Lilly, and Structure Therapeutics.

The first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist delivered superior A1C reduction and weight loss at 40 weeks in people with type 2 diabetes.

ATTD 2026 reveals AI “digital twins,” next-gen closed-loop pumps, and sensors that boost time-in-range and ease diabetes management.

The MiniMed Flex is a discreet, smartphone-controlled insulin pump that is roughly the size of 2 stacked insulin vials.

Catch up with FDA decisions, key trial results, podcast updates, and more.

Isaacs and Bellini discuss recent updates on Eli Lilly's orforglipron and retatrutide and Novo Nordisk's UBT251, along with other recent GLP-1 news.

Parent company Eli Lilly has released full data from ACHIEVE-3, indicating superior weight loss and A1C reductions with orforglipron 12 mg and 36 mg.

The list price of all 3 semaglutide drugs will be lowered to $675, marking a reduction of roughly 50% and 35% for Wegovy and Ozempic, respectively.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the Portal Pump's recent Breakthrough Designation from the FDA.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the Portal implanted insulin pump, which has received Breakthrough Device designation from the FDA.

1 year into real-world use, 4 clinicians discuss how semaglutide is transforming the endocrinology, nephrology, and cardiology landscape.

Diabetes Dialogue Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the patient awareness motivation behind Novo Nordisk’s recent announcement.

Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the controversy surrounding Hims and Hers and the risks of compounding GLP-1 formulas.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Ozempic’s approval in a higher-dose oral form and lingering concerns over compounded drugs.

This secondary analysis of the phase 3b SOUL cardiovascular outcomes trial indicates oral semaglutide’s potential capacity to reduce HF events.

Catch up with major trial results, key FDA approvals, and more.

The investigational dual GLP-1/GIP receptor agonist resulted in substantial weight loss without plateau after 48 weeks in patients with obesity.

Lund highlights the value of preventive treatment in patients with prediabetes on the environment via reduced greenhouse gas emissions.

Fonseca explains the structure and goals of the ongoing trial, which has enrolled its first patient to clofutriben treatment against hard-to-control T2D.

Lund discusses a recent study detailing the comparatively lower greenhouse gas emissions caused by preventive care versus diabetes management.

This segment of Diabetes Dialogue spotlights the FDA clearance of the MiniMed Go and its collaborative capacity with various other devices.

Weintraub discusses how patients with overweight or obesity, regardless of T2D, will regain weight in varying degrees after discontinuing therapy.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review tech updates from Sequel Med Tech, Diabeloop, and Medtronic.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Susan Weiner, MS, to discuss the recently released US Dietary Guidelines.